TAE Life Sciences

United States
California, Maryland, United States

Company profile

TAE Life Sciences company profile

TAE Life Sciences is developing a novel biological-targeting radiation therapy based on Boron Neutron Capture Therapy (BNCT) to improve the lives of patients with rapidly spreading, invasive and recurrent cancers that do not respond to other cancer therapies. TLS is the only company with a comprehensive target drug and neutron technology product portfolio to enable next-generation combination cancer therapy as a first-line treatment for patients globally.

Business identity

Contact email
[email protected]
Operating status
Active
Company type
For Profit
Employee range
51-100 employees
Revenue range
$0-$1M
Founded
2017-01-01, Year

Headquarters

Country code
US
Continent
North America

Capital profile

Funding and company signals

Funding stage
Early Stage Venture
Funding rounds
3
Total equity funding
$70M
Last funding
Series B / $30M / 2020-06-02
Last equity funding
Series B / $30M
Investors
2
Lead investors
1
Founders
1
Articles
63

Founders and investors

Founders

Bruce Bauer

Lead investors

Artis Ventures

Investors

Artis VenturesBig Sky Partners